Zinc Oxide Versus Petrolatum Following Skin Surgery
Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respect
| Condition(s) | Surgical Incision, Surgery--Complications, Surgical Wound, Surgical Site Infection, Scar, Hypertrophic Scar |
|---|---|
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Study type | Interventional |
| Summary | Patients undergoing routine surgery in the Department of Dermatology for any indication on non-scalp skin and closed in linear fashion with scar greater than or equal to 4.5cm in length will be invited to participate in this split scar, head to head study comparing zinc oxide and petrolatum. Patients will apply respective ointments to each half of scar daily for one month and maintain a log of these activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale (POSAS), a quantitative objective assessment of scar appearance. Trained observers (board-certified dermatologists) will score the observer portion of the scale. POSAS outcomes, post-operat |
| Who can participate | Inclusion Criteria: 1. ≥ 18 years of age 2. Linear closure, non-scalp site 3. ≥ 4.5 cm in length (final incision/closure length) 4. End to end symmetry (surgical site is not grossly asymmetric from end to end) 5. Grossly uninfected site Exclusion Criteria: 1. ≤ 18 years 2. Visibly asymmetric linear scar 3. Grossly infected surgical site 4. History of allergy to topical zinc oxide |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Melissa Pugliano-Mauro |
| Locations | Pittsburgh, PA, Pennsylvania, United States |
| Start date | 2021-09-01 |
| NCT ID | NCT03561376 |
| Official listing | https://clinicaltrials.gov/study/NCT03561376 |